The RNA Society is a non-profit international scientific society with more than 1800 members dedicated to fostering research and education in the field of RNA science. @RNASociety
The “RNA Collaborative Seminar Series,” initiated and led by the Center for RNA Biomedicine, is promoted by the RNA Society (website and Twitter). As of June 2023, it connected 26 RNA research centers and has hosted bi-weekly seminars with about 100 participants attending each seminar.
The goal of the RNA Collaborative is to cross promote RNA research and strengthen and connect the RNA scientific community. The RNA Collaborative has over 30 member institutions from across the world. The RNA Society partners with the RNA Collaborative and supports its webpage.
The RNA Collaborative is a grassroots effort led by a number of RNA research centers worldwide to provide an online seminar series during and beyond the institutional shutdown caused by COVID-19. The goal of the program is to promote and disseminate emerging RNA research and to establish and strengthen connections within the international RNA scientific community. Scientists are welcome to present all RNA-related research spanning from foundational discoveries to potential therapeutic applications. Host centers can choose to present an hour-long seminar, two 30-minute seminars, four
poster sessions with introductory lightning talks, or a combination of talks and poster sessions.
The RNA Collaborative offers a seminar series organized by the RNA Centers of each partner institutions. The seminars take place every other week, on Wednesdays, either from 9:00–10:00 a.m. or 4:00–5:00 p.m. EST.
For more information, visit https://www.rnasociety.org/rnacollaborative-seminar-series
RNA therapeutics have the potential to revolutionize the treatment of a wide range of medical conditions and improve the lives of patients across the globe. The Society for RNA Therapeutics (SRT) was founded with the goal of advancing RNA Therapeutics research, education, and technological advancements for the benefit of world health.
The SRT is a global network to support translational research and development of RNA therapeutics; establish standards for RNA manufacturing; create guidelines for clinical trials; facilitate public-private regulatory partnerships; promote accessibility of RNA therapeutics for all patients; offer public and professional education; create training guidelines; promote the interests of patients with diseases amenable to RNA therapies; and create clinical best practices.
For more information, visit https://srnat.org/
The Experimental Drug Development Center (EDDC) in Singapore is excited to share our commitment with the University of Michigan Center of RNA Biomedicine to innovate and excel in the pioneering field of small molecule targeting RNA.
As a beacon of innovation in Singapore, EDDC is a nationally recognized entity for drug discovery and development, hosted by the prestigious Agency for Science, Technology & Research (A*STAR). Our mission is to translate discovery research into therapeutics through strategic collaboration and the pursuit of scientific excellence.
EDDC is dedicated to the mission of translating Singapore’s extensive scientific knowledge into effective medicines. Our primary focus revolves around pioneering work in small molecule targeting RNA, representing a groundbreaking approach with significant implications across various diseases for therapeutic intervention. This mission underscores our commitment to address diseases with high unmet medical needs by expanding the druggable target space and targeting >90% of RNA in the human genome.
We invite University of Michigan faculty members to explore with us the exciting field of translating RNA-driven diseases into therapeutic interventions. Collaboratively, we aim to develop small molecule
drugs that target RNA through the integration of cutting-edge RNA discoveries from the U-M Center of RNA Biomedicine and EDDC’s innovative small molecule targeting RNA platform. Let us embark on a collaborative journey that not only explores new frontiers but also pushes the boundaries of drug discovery and development in the rapidly emerging field of RNA therapeutics.
We look forward to fostering a dynamic exchange of ideas and insights
between our institutions and jointly contributing to the forefront of scientific and medical innovation.
To learn more, visit https://www.eddc.sg/
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care.
For more information, visit https://www.cff.org/
The work being done at the University of Michigan Center for RNA Biomedicine helps progress the foundation’s quest to cure cystic fibrosis. To apply for an award in cystic fibrosis research or professional training or development, review current and upcoming academic funding opportunities.
For more information, visit https://www.cff.org/researchers/academic-funding-opportunities
Newsroom
U-M Researchers Collaborate on $3 Million Grant to Treat Rare Forms of Cystic Fibrosis
Center RNA Therapeutics Director Michelle Hastings, and faculty members Rachel Niederer and Alexandra Piotrowski-Daspit address the need for new treatment strategies, and the subsequent barriers that must be overcome for success, by working together as an interdisciplinary team with unique expertise in CFTR physiology, designing RNA therapeutics, identifying targetable regulatory sequences, and developing engineered delivery vehicles for therapeutic molecules.